miR-1293通过调节对西斯丁治疗的药物敏感性来抑制骨髓瘤的进展
Tingxuan Wang1, Jincheng Huang2, Gang Chen3
1Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Department of Spinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510005, China.
International immunopharmacology
|February 17, 2024
概括
这项研究表明,增加miR-1293水平可以提高骨髓瘤化疗的有效性. 在患者中较高的miR-1293预测了更好的结果,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 化疗是骨髓瘤的主要治疗方法,但耐药性和毒性限制了其有效性.
- 新的治疗目标对于改善骨髓瘤患者的化疗结果至关重要.
研究的目的:
- 确定增强骨髓瘤中西斯丁敏感性的新机制.
- 研究miR-1293作为骨髓瘤潜在治疗点的作用.
主要方法:
- 在骨髓瘤患者中分析miR-1293表达水平.
- 研究基底的分子机制 miR-1293调节的西斯.
- 在体外和体内验证miR-1293在抑制骨髓瘤进展方面的功能.
主要成果:
- 瘤抑制剂miR-1293的升调增强了骨髓瘤中西斯普拉丁的敏感性.
- 化疗前较高的miR-1293水平与患者的预后相对相关.
- miR-1293对TIMP1进行向,使Notch1/Hes1和TGFBR1/Smad2/3通路失活,从而促进瘤细胞死亡.
结论:
- miR-1293代表了一种新的机制,用于增强骨髓瘤中西斯丁的敏感性.
- 化疗前的miR-1293补充剂是骨髓瘤的潜在治疗策略.
- miR-1293作为一个有前途的生物标志物用于预测骨髓瘤治疗反应.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K